The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.

Inclusion Criteria:

• Patient must provide written informed consent prior to participating in this protocol
• Patient must have been prescribed TECELRA®
• Patient's commercially manufactured product does not meet the commercial release specification
• Repeat manufacture is not feasible or is not clinically appropriate per Investigator assessment in consultation with Adaptimmune
• Repeat leukapheresis is not feasible or is not clinically appropriate per Investigator assessment
• The Investigator has confirmed a favorable benefit:risk profile, following sponsor evaluation of the NC afami-cel, and deems proceeding with treatment under this EAP is in the best interest of the patient
• Patient deemed medically fit and stable to receive NC afami-cel per Investigator assessment
• Female patients with reproductive potential must have a negative serum or urine pregnancy test within 7 days of initiating lymphodepleting chemotherapy

Exclusion Criteria:

• Patient has contraindication(s) as per the TECELRA® USPI
• Do not use TECELRA® in adults who are heterozygous or homozygous for HLA-A*02:05P